OncoTargets and Therapy (Apr 2021)

Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases

  • Cao JZ,
  • Pan JF,
  • Ng DM,
  • Ying MQ,
  • Jiang JH,
  • Ma Q

Journal volume & issue
Vol. Volume 14
pp. 2797 – 2803

Abstract

Read online

Jian-zhou Cao,1,2 Jin-feng Pan,1,2 Derry Mingyao Ng,1,3 Meng-qi Ying,1 Jun-hui Jiang,4,5 Qi Ma2– 5 1Medical School, Ningbo University, Ningbo, Zhejiang, 315211, People’s Republic of China; 2Comprehensive Urogenital Cancer Center, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315010, People’s Republic of China; 3Translational Research Laboratory for Urology, The Key Laboratory of Ningbo City, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315010, People’s Republic of China; 4Department of Urology, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315010, People’s Republic of China; 5Ningbo Clinical Research Center for Urological Disease, Ningbo, Zhejiang, 315010, People’s Republic of ChinaCorrespondence: Jun-hui Jiang; Qi MaNingbo First Hospital, 59 Liuting Street, Ningbo, Zhejiang, 315010, People’s Republic of ChinaTel +86 13967810338; +86 15958800971Email [email protected]; [email protected]: Prostate cancer (PCa) is one of the most common types of malignancy, most patients with PCa will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), which has a poor prognosis. Since 2004, chemotherapy has been approved by the FDA as the first-line treatment for mCRPC, and docetaxel-based regimens have been shown to improve both the patients’ symptoms and overall survival (OS). 10 cycles of docetaxel therapy are usually given to patients with mCPRC, but there is still no consensus on the optimal number of treatment cycles. Here, we present three cases of mCRPC patients that received maintenance long-term multiple-cycles docetaxel treatment. We believe that this new treatment strategy may benefit carefully selected mCRPC patients and provide several key advantages such as maximum exposure to drugs, improvements in drug efficacy, and reduce the risk of developing drug resistance.Keywords: metastatic castration-resistant prostate cancer, docetaxel, maintenance long-term multiple chemotherapy

Keywords